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Abstract  
Although displaying genetic correlations, psychiatric disorders are clinically defined as categorical entities 
as they each have distinguishing clinical features and may involve different treatments. Identifying differential 
genetic variations between these disorders may reveal how the disorders differ biologically and help to guide 
more personalized treatment. 
Here we presented a comprehensive analysis to identify genetic markers differentially associated with 
various psychiatric disorders/traits based on GWAS summary statistics, covering 18 psychiatric 
traits/disorders and 26 comparisons. We also conducted comprehensive analysis to unravel the genes, 
pathways and SNP functional categories involved, and the cell types and tissues implicated. We also assessed 
how well one could distinguish between psychiatric disorders by polygenic risk scores(PRS).  
SNP-based heritabilities(h2SNP) were significantly larger than zero for most comparisons. Based on current 
GWAS data, PRS have mostly modest power to distinguish between psychiatric disorders. For example, we 
estimated that AUC for distinguishing schizophrenia from major depressive disorder(MDD), bipolar 
disorder(BPD) from MDD and schizophrenia from BPD were 0.694, 0.602 and 0.618 respectively, while the 
maximum AUC(based on h2SNP) were 0.763, 0.749 and 0.726 respectively. We also uncovered differences in 
each pair of studied traits in terms of their differences in genetic correlation with comorbid traits. For example, 
clinically-defined MDD appeared to more strongly genetically correlated with other psychiatric disorders and 
heart disease, when compared to non-clinically-defined depression in UK Biobank. 
Our findings highlight genetic differences between psychiatric disorders and the mechanisms involved. PRS 
may aid differential diagnosis of selected psychiatric disorders in the future with larger GWAS samples.  
 
Introduction 
  Psychiatric disorders are common and more than one-third of the population suffer from at least one kind of 
disorder in their life(1). Psychiatric disorders also rank among the top in terms of total disability-adjusted life 
years (DALYs)(2) lost. Studies have revealed that psychiatric disorders generally have moderate to high 
heritability, likely contributed by a large number of genes, and common variation plays a substantial role(3, 4). 
Recent analyses based on genome-wide association studies (GWAS) have suggested a moderate to high 
genetic correlation between many psychiatric disorders(5, 6). On the other hand, although displaying strong 
genetic correlations, these disorders are clinically defined as independent categorical entities as they each have 
distinguishing clinical symptoms and often require different treatments(7). Identifying differential genetic 
variations between these disorders may shed light on how the disorders differ biologically and help to guide 
more personalized treatment in the future. Another potential clinical application is that genetic markers may 
help differential diagnosis (DDx) of related disorders. For example, a patient who presents with depression for 
the first episode may actually be having bipolar disorder(BPD). It is often difficult to distinguish the two 
diagnoses by clinical features alone at the first presentation, but their treatments are very different. If genetic 
information can help differentiate BPD from unipolar depression, it will enable more appropriate treatments 
given at an earlier stage of illness.  
Most genetic studies to date have been focusing on identifying shared loci or genetic overlap between 
psychiatric disorders (8). An effort to explore genetic architecture differences between BPD and SCZ was 
made by a recent study(9, 10). They first compared 9,252 BPD cases to 7,129 SCZ cases but did not find any 
SNPs reaching genome-wide significance(9); however, polygenic risk score (PRS) analysis showed that the 
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score significantly differed between SCZ and BPD patients, indicating that differences between the two 
disorders have a genetic basis. More recently, they conducted an association analysis with a larger sample size 
(23,585 SCZ cases and 15,270 BPD cases) and identified two genome-wide significant SNPs(10). However, 
the above analyses require individual genotyping data, which might be difficult to access due to privacy 
concerns. In addition, many of the largest GWAS analyses were conducted by meta-analyses and typically 
only summary statistics were available. 
   Here we presented a comprehensive analysis to identify differential genetic markers covering 18 
psychiatric disorders/traits and 26 comparisons, based on GWAS summary statistics. The analytic framework 
was successfully validated by simulation studies before application. Our results based on GWAS summary 
data showed almost perfect genetic correlation with those obtained via comparing BPD and SCZ individual 
genotyping data (10)(rg = 1.054, se = 0.025), suggesting that our approach is reliable and resembles results 
from individual-level data analysis.    
Importantly, we also conducted in-depth analysis to reveal the genes and pathways involved, and which 
cell types and tissues were the most relevant in differentiating the disorders. We also uncovered differences in 
each pair of disorders in terms of how they are genetically related to different sets of comorbidities. Another 
novel contribution is that by applying a recently developed methodology (11), we assessed how well we could 
distinguish two psychiatric disorders (e.g., major depressive disorder[MDD] vs BPD) using PRS from existing 
GWAS data, as well as the maximum discriminating ability from all GWAS-panel variants. This may be 
clinically relevant in the future given the lack of biomarkers to aid differential diagnosis (DDx) of psychiatric 
disorders.  
 
Methods 
GWAS summary statistics 
A set of GWAS summary statistics for 18 psychiatric disorders/traits were included (Table 2) which were 
obtained from several public databases, for example the Psychiatric Genomics Consortium (PGC, 
https://www.med.unc.edu/pgc/), the Complex Trait Genetics lab (CTG lab, https://ctg.cncr.nl/) and the UK 
Biobank (UKBB, http://www.nealelab.is/uk-biobank). Details of each dataset are given in Table 2 and 
references therein (12-24).  
 
We included a total of 10 psychiatric disorders in our analysis, including MDD, post-traumatic stress 
disorder(PTSD), eating disorder (ED), schizophrenia (SCZ), bipolar disorder (BPD), autistic spectrum 
disorder (ASD), attention deficit/hyperactivity disorder (ADHD), anxiety disorder, obsessive-compulsive 
disorder (OCD) and alcohol dependence. Besides, we also included three other depression-related phenotypes 
to be compared against MDD from PGC. These 3 phenotypes were based on the UKBB sample, including 
longest period of feeling low/depressed, seen doctor (GP) for nerves, anxiety, tension or depression (to 
represent self-reported non-specific depression/low mood), and probable recurrent major depression (severe). 
The latter was derived from several questions based on Smith et al. (25). In addition to the above, we also 
included ever used cannabis, insomnia, suicide attempts (SA), neuroticism and psychotic experience in our 
analysis as they are closely related to many psychiatric disorders.  
 
For MDD which formed a major part of our comparisons, a recent GWAS meta-analysis was carried out 
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based on 135,458 cases and 344,901 controls(26). Excluding 23andMe data, the released GWAS summary 
statistics were generated from a sample set of 59,851 cases and 113,154 controls with a higher SNP-based 
heritability (7.8%, se = 0.5%). The majority of MDD cases (45591 of 59851 cases, ~76.2%) in this sample 
were defined by clinical assessment or clinical records according to ICD/DSM criteria, although the UKBB 
sub-sample (14260/59851 cases) included some cases from self-reporting. While an updated study(27) 
included a larger sample, the majority (excluding 23andMe) was composed of the broad depression phenotype 
in the UK Biobank dataset (127552 out of 170756 cases); the sample also showed a lower SNP-based 
heritability (6.0%, se = 0.3%)(27). A recent study showed that genetic studies on depression defined by 
minimal or ‘broad’ phenotyping may not be specific to MDD itself(28). Such studies might identify 
non-specific genetic factors linked to other psychiatric conditions; this may defy our purpose of finding 
differential genetic markers between related disorders/traits.  
 
Identification of differential genetic markers 
For further quality control, SNPs with a low imputation quality score (INFO R2 < 0.6) were excluded from 
further analysis. In addition, indels and duplicated SNPs were filtered. We then performed a harmonization 
step to keep the reference allele for signed test statistics consistent between each pair of GWAS datasets. 
Following that, the post–quality-control and harmonized summary statistics were utilized for investigating 
differential genetic variants for 26 comparisons of psychiatric disorders/traits (Table 3) using a statistical 
method presented below. 
 
  We present an analytic approach capable of unravelling the genetic differences between a pair of 
disorders/traits, relying only on GWAS summary statistics. The method also allows overlap in study samples. 
In essence, we are ‘mimicking’ a case–control GWAS in which the cases are subjects affected with one 
disorder and controls affected with the other disorder. 
 
Suppose 𝑇ଵ and  𝑇ଶ are two binary traits under study. Let 𝑆 be a biallelic SNP, coded as 0,1 or 2. For 
simplicity, we first assume this is a prospective study of a population-based sample. Based on the principles of 
logistic regression, we have 
log ൬
𝑃(𝑇ଵ = 1)
𝑃(𝑇ଵ = 0)
൰ = log (
𝑝ଵ
1 − 𝑝ଵ
)  =  𝛽଴ଵ +  𝛽ଵଵ𝑆 + 𝜀ଵ 2.1 
log ൬
𝑃(𝑇ଶ = 1)
𝑃(𝑇ଶ = 0)
൰ = log (
𝑝ଶ
1 − 𝑝ଶ
)  =  𝛽଴ଶ + 𝛽ଵଶ𝑆 + 𝜀ଶ 2.2 
log ൬
𝑃(𝑇ଵ = 1)
𝑃(𝑇ଶ = 1)
൰ = log (
𝑝ଷ
1 − 𝑝ଷ
)  =  𝛽଴ଷ + 𝛽ଵଷ𝑆 + 𝜀ଷ 2.2 
where 𝑝ଵ = 𝑃(𝑇ଵ = 1) and 𝑝ଶ = 𝑃(𝑇ଶ = 1) denote the probability of the corresponding traits in the 
collected dataset; 𝜀௜(𝑖 = 1,2,3) indicates the error term for corresponding regression model. Based on the 
definition of odds ratio (OR), for traits 𝑇ଵ and 𝑇ଶ, we have: 
𝑂𝑅(𝑇ଵ𝑣𝑠 𝑐𝑡𝑟𝑙) =  𝑒ఉభభ =  
୔୰ ( భ்ୀଵ|ௌୀ௦ାଵ,௖௢௩௔௥௜௔௧௘௦)
୔୰ ( భ்ୀ଴|ௌୀ௦ାଵ,௖௢௩௔௥௜௔௧௘௦)
/୔୰ ( భ்ୀଵ|ௌୀ௦,௖௢௩௔௥௜௔௧௘௦)
୔୰ ( భ்ୀ଴|ௌୀ௦,௖௢௩௔௥௜௔௧௘௦)
 2.3 
𝑂𝑅(𝑇ଶ 𝑣𝑠 𝑐𝑡𝑟𝑙) =  𝑒ఉభమ =  
୔୰ ( మ்ୀଵ|ௌୀ௦ାଵ,௖௢௩௔௥௜௔௧௘௦)
୔୰ ( మ்ୀ଴|ௌୀ௦ାଵ,௖௢௩௔௥௜௔௧௘௦)
/୔୰ ( మ்ୀଵ|ௌୀ௦,௖௢௩௔௥௜௔௧௘௦)
୔୰ ( మ்ୀ଴|ௌୀ௦,௖௢௩௔௥௜௔௧௘௦)
 2.4 
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Suppose the controls for the two studies come from the same population. In this regard, 
Pr(𝑇ଵ = 0|𝑆 = 𝑠 + 1, 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠)  and Pr(𝑇ଵ = 0|𝑆 = 𝑠, 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠)  are approximately the same as 
Pr(𝑇ଶ = 0|𝑆 = 𝑠 + 1, 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠) and Pr(𝑇ଶ = 0|𝑆 = 𝑠, 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠) respectively. Thus, the odds ratio 
(OR) for differential association between the two diseases can be given as: 
𝑂𝑅(𝑇1 𝑣𝑠 𝑇2) =  𝑒ఉభయ =  ୔୰( భ்ୀଵ|ௌୀ௦ାଵ,௖௢௩௔௥௜௔௧௘௦)
୔୰( మ்ୀଵ|ௌୀ௦ାଵ,௖௢௩௔௥௜௔௧௘௦)
 /୔୰( భ்ୀଵ|ௌୀ௦,௖௢௩௔௥௜௔௧௘௦)
୔୰( మ்ୀଵ|ௌୀ௦,௖௢௩௔௥௜௔௧௘௦)
 
≈
(୔୰( భ்ୀଵ|ௌୀ௦ାଵ,௖௢௩௔௥௜௔௧௘௦)
୔୰( భ்ୀ଴|ௌୀ௦ାଵ,௖௢௩௔௥௜௔௧௘௦)
/୔୰( భ்ୀଵ|ௌୀ௦,௖௢௩௔௥௜௔௧௘௦)
୔୰( భ்ୀ଴|ௌୀ௦,௖௢௩௔௥௜௔௧௘௦)
) ÷
(୔୰( మ்ୀଵ|ௌୀ௦ାଵ,௖௢௩௔௥௜௔௧௘௦)
୔୰( మ்ୀ଴|ௌୀ௦ାଵ,௖௢௩௔௥௜௔௧௘௦)
/୔୰( మ்ୀଵ|ௌୀ௦,௖௢௩௔௥௜௔௧௘௦)
୔୰( మ்ୀ଴|ௌୀ௦,௖௢௩௔௥௜௔௧௘௦)
) 
= 𝑒ఉభభିఉభమ 
2.5 
 
In other words, the effect size of differential association (i.e. trait 1 as case and trait 2 as control) can be 
derived from the difference of effect sizes of the respective traits. The variance of 𝛽ଵଷ can be expressed as: 
𝑉𝑎𝑟(𝛽ଵଷ) = 𝑉𝑎𝑟(𝛽ଵଵ − 𝛽ଵଶ) = 𝑉𝑎𝑟(𝛽ଵଵ) +  𝑉𝑎𝑟(𝛽ଵଶ) − 2𝐶𝑜𝑣(𝛽ଵଵ, 𝛽ଵଶ) 2.6 
𝐶𝑜𝑣(𝛽ଵଵ, 𝛽ଵଶ) depends on the actual overlap between the samples and the correlation between the 2 
phenotypes. It can be derived from multiplying the SEs of the two coefficients with the intercept from 
cross-trait LD score regression (see equation 6 in (29)). Note that the above derivations only require the 
regression coefficients (beta), which is the same under a prospective (population-based) or a retrospective 
design (case-control design where cases may be over- or under-sampled) (30).  
 
  Two studied traits (neuroticism and longest period of feeling depressed/low) were continuous traits. To 
be consistent with other comparisons which all involves binary traits/disorders, we considered the summary 
statistics of a corresponding case-control study in which subjects at top 20% of the outcome are considered as 
‘cases’. The method for deriving binary-trait summary statistics was described in another work (31). After 
computing the differential genetic associations, to further protect against population stratification, we 
performed genomic control following (32) (genomic inflation factor was based on LD score regression result). 
 
To further check the validity of our approach, we also computed genetic correlation of the results from a 
GWAS of BPD vs SCZ from our analytic method against those obtained by comparing the two disorders 
directly using individual genotype data, as reported in ref (10).  
 
Functional annotations of identified differential genetic markers 
  The differential genetic variants identified were further explored for their biological functions using FUMA 
(https://fuma.ctglab.nl/)(33). Following the definition by FUMA, independent significant SNPs were defined 
as those with p<5e-8 and independent from each other at the default r2 threshold (r2=0.6). For the definition of 
genomic loci, independent significant SNPs which are correlated with each other at r2 ≥ 0.1 are assigned to the 
same risk locus. Independent significant SNPs which lie within 250 kb are also merged into one genomic risk 
locus. All candidate SNPs in defined risk loci that are in LD (r2≥0.6) with the corresponding independent 
significant SNPs were selected for functional annotations, mainly including combined annotation-dependent 
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depletion (CADD) scores(34), chromatin states(35, 36), ANNOVAR categories(37) and RegulomeDB 
scores(38).  
 
Gene mapping 
  SNPs were mapped to genes in FUMA using three different strategies including mapping by position, 
expression quantitative trait loci (eQTL), and chromatin interactions (CI). In brief, the positional method maps 
variants to genes based on their physical position, while the eQTL strategy maps SNPs to genes with which a 
significant (FDR<0.05) eQTL association exists. The third strategy (CI) maps SNPs to genes based on 
three-dimensional (3D) DNA-DNA interaction of the SNP and gene regions.  
 
Genome-wide gene-based association study (GWGAS) and tissue/cell-type enrichment analysis 
 P-values from SNP-based analysis were utilized for GWGAS analysis in MAGMA (39). The program 
aggregates statistical significance of SNPs within a gene to output a gene-based statistic. Multiple testing was 
corrected by the false discovery rate (FDR) approach. In our gene-based and other analyses to follow, results 
with FDR<0.05 were considered significant.  
 
The biological functions of GWGAS-significant genes were further investigated via tissue and cell-type 
expression enrichment analysis using MAGMA (39) and Linkage Disequilibrium SCore regression (LDSC) 
(32). In tissue enrichment analysis, MAGMA was used to test for enrichment based on over-representation of 
differentially expressed genes (DEGs) in each of 53 tissues in GTEx. We observed that brain regions were 
predominantly enriched in the above analysis; hence we focused subsequent analyses on the brain. Next we 
conducted an enrichment analysis within 13 brain regions using LDSC, based on GTEx data. This is a 
‘competitive’ analysis restricted to the brain; the aim was to reveal enrichment within specific brain regions 
when compared to other regions.  
 
Following that, all available single-cell expression datasets from human brain regions [Lateral Geniculate 
Nucleus (LGN), Middle Temporal Gyrus (MTG), hippocampus, cortex, prefrontal cortex, midbrain and 
temporal cortex] in FUMA were included for enrichment analysis to explore the specific types of contributing 
cells/neurons. A 2-step workflow was implemented for the enrichment analysis. The 1st step was carried out to 
identify significantly enriched cell types, which were retained for the 2nd step to determine independent signals 
within a dataset by stepwise conditional analysis (see also https://fuma.ctglab.nl/tutorial#celltype). 
 
We also conducted pathway and gene-set enrichment analyses to explore whether these significantly 
associated genes were significantly enriched in biological predefined pathways or gene ontology (GO) sets 
based on the ConsensusPathDB database (CPDB, human) (http://consensuspathdb.org/)(40).  
 
SNP-based heritability and genetic correlation with related traits 
SNP-based heritability (h2snp) of differential genetic associations was estimated by LDSC and SumHer (41). 
The former is the most widely used approach for estimating h2snp, and was employed as the primary estimation 
method here. We also performed additional analysis with SumHer, another program for h2snp estimation that 
allows more realistic heritability models. We also conducted ‘partitioned heritability’ analysis to identify 
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which functional categories of genetic variants (e.g coding, promoter, histone marks, enhancers etc.) 
contribute the most to differentiation of the psychiatric disorders/traits (42).  
 
In addition to shedding light on genetic architecture and relative importance of different functional 
categories, heritability explained is connected to the predictive power of genetic variants (43). In this regard, 
we also estimated the maximum ‘predictive ability’ (ability to differentiate the disorders in our case) that can 
be achieved if all variants on the GWAS panel are accounted for. Liability-scaled SNP-based heritability (h2snp) 
was calculated using LDSC, with sample and population prevalence as input. We estimated the ‘sample 
prevalence’ by the effective number of cases(44) in the two datasets. We then followed the methodology 
described in (43) to compute different predictive indices and graphs. Briefly, we computed the AUC under 
ROC curve, proportion of cases explained by those at the top k% of predicted risk, variance of predicted risk 
and the absolute risk at different percentile. The graphs included ROC curve, predictiveness curve and the 
probability and cumulative density function of predicted risks. The analysis on differentiating ability was 
performed on comparisons of selected psychiatric disorders (SCZ, BPD, ED, ASD, ADHD, anxiety disorders, 
PTSD, OCD) and clinical symptoms (psychotic experience) for which differential diagnosis is considered 
more clinically relevant.  
 
Genetic correlations (rg) between the differential genetic variations and 42 potentially related phenotypes 
were calculated using LDSC(http://ldsc.broadinstitute.org/centers/)(45). Generally, rg reflects how much the 
non-shared or unique genetic component of the 1st disorder is genetically correlated with a specific trait, when 
compared to the 2nd disorder in the pair. The rationale of this analysis is that when we consider two disorders 
as different, it is important to see whether they are associated with different comorbid disorders/traits. This 
distinction is important to help understand the different prognosis or aetiology of different disorders. For 
example, SCZ is generally associated with more prominent cognitive deficits than BPD. The above analysis 
may help to highlight such differences. 
 
  A set of 42 GWAS summary statistics were obtained from the LD-Hub(45) and grouped into nine categories 
of traits including neurological diseases, personality traits, sleeping, cognitive, education, brain volume, 
psychiatric disorders, cardiometabolic traits and aging.  
 
Ability of polygenic risk scores (PRS) from existing GWAS data to differentiate disorders 
For selected traits for which differential diagnosis (DDx) are more clinically relevant, we performed another 
analysis to evaluate the ability of polygenic risk scores (PRS) from existing GWAS data to distinguish 
psychiatric disorders. The PRS was based on a case-control study of the corresponding disorders (disorder A 
as ‘case’ and disorder B as ‘control’). Note that unlike above, we are not focusing on the maximum predictive 
power achievable from all common variants.   
An empirical Bayes approach has been proposed to recover the underlying effect sizes and could be used to 
forecast predictive ability of PRS, based on summary statistics alone(11). The method has been verified in 
simulations and real data applications(11). Eighteen subsets of genetic variants based on a series of P-value 
thresholds (1 × 10−5, 1 × 10−4, 5 × 10−4, 1 × 10−3, 5 × 10−3, 0.01, 0.03, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 
0.9, and 1) were used to construct PRS.  
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Simulation 
  To verify the validity of our proposed method in uncovering genetic differences among related disorders, 
we simulated different sets of genotype-phenotype data assuming 300 SNPs (i.e., Nsnp = 300; coded as 0, 1 and 
2) and two disorders. Since the proposed framework is principally a SNP-based analysis, the number of 
simulated genotypes will not affect the validity of the simulation. Allele frequency for each simulated SNP 
was randomly generated from a uniform distribution within [0.05, 0.95]. The number of subjects with each 
disorder (i.e., ncases) was set to [10000, 20000, 50000, 100000] with a disease prevalence (K) of 10%. Here, 
ncases denotes the expected number of cases in the whole simulated population cohort. Given the disease 
prevalence, the whole simulated population cohort (ntotal) i.e. 𝑛𝑡𝑜𝑡𝑎𝑙 = ௡௖௔௦௘௦
௄
. The total SNP-based 
heritability (h2snp) for each trait was set at 0.2 to 0.4, distributed among all SNPs.  
More specifically, we simulated standard normal variables zi~ N(0,1), and set mean effect size µ =  
ට ௛
మ
ேೞ೙೛
  . The actual effect size for SNPi was set at βi =µ * zi. The total liability y equals the sum of effects 
from each SNP plus a residual (e), i.e. 𝑦 = ∑ 𝛽௜𝑥௜௜ + 𝑒; the total variance of y was set to one. Following the 
liability threshold model, subjects with total liability exceeding a certain threshold [= Φିଵ(𝐾), where K is the 
disease prevalence] are regarded as having the trait/disease. The non-shared genetic covariance between the 
two traits was set to 0.1. 
    From the simulated population cohort, we simulated two case-control studies with trait A and B as the 
outcome respectively. Suppose the number of cases for trait A and B in the simulated population cohorts are 
respectively 𝑁஺ and 𝑁஻, and 𝑁 = 𝑚𝑎𝑥(𝑁஺, 𝑁஻). For trait A, we picked 𝑁஺ cases and 2𝑁 − 𝑁஺ controls 
from the population. As for trait B, we picked 𝑁஻ cases and 2𝑁 − 𝑁஻ controls from the population. For 
comparison, we also simulated a “real” GWAS comparing the two disorders. All cases who are identified as 
having trait A but not trait B were selected as cases (𝑁஺_௢௡௟௬); all cases who are identified as having trait B but 
not trait A are selected as controls (𝑁஻_௢௡௟௬). To demonstrate the validity of our current method, we also 
simulated case-control samples with different overlap rate (P) for both traits. Here, P indicated the ratio of 
overlapped samples and all picked samples for each case-control study, i.e., 𝑃 =  𝑁௖௧௥௟.௢௩௘௥௟௔௣ 2𝑁⁄ . To adjust 
the overlap rate, we adjust the number of common controls for both traits (as in practice the overlap more 
often occurs in controls).  
 
Results 
Please note that all supplementary tables are available at  
https://drive.google.com/open?id=1qrpDV6GhobffSwOtRsmAkPY_CihIpHuA 
 
Simulation results 
Table 1 demonstrates our simulation results (please also refer to Table S0). The correlations between the 
estimated and actual coefficients for the GWAS analysis are very high with different sample sizes of cases. As 
shown in Table 1, the correlation and RMSE improved with increased sample size and overlap rate. Since the 
sample sizes for current GWAS summary data are usually larger than 10,000, our proposed method should be 
sufficiently good to approximate the coefficients from GWAS summary data of corresponding traits. As 
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expected, power increases with larger case sizes and heritability explained by SNPs. In addition, there was no 
observed inflated type I error at a p-value threshold of 0.05. 
 
Identification of genetic variants differentiating the psychiatric disorders/traits 
For the 18 sets of included GWAS summary statistics (Table 2), we applied the proposed methods to identify 
differential genetic variants for a total of 26 pairs of comparisons (Table 3). In principle, we selected traits 
which are similar in nature or commonly comorbid for comparison. The SNP-based heritabilities are presented 
in Table 3.  
 
These comparisons may be divided into five groups, including major depressive disorder (MDD) vs. other 
psychiatric disorders/traits, MDD vs. depression-related traits, neuroticism vs. psychiatric disorders, psychotic 
experiences vs. three psychiatric disorders and others (Table 3). Altogether, we identify a total of 11,410 
significantly associated differential genetic variants (P<5e-08) and these variants in each comparison could 
form up to 1,398 genomic risk loci based on linkage disequilibrium block (Table 3).  
 
MDD against psychiatric disorders/outcomes 
  In this part, we compared MDD with 12 different psychiatric disorders/outcomes, including SCZ, BPD, ED, 
ASD, ADHD, anxiety disorder, insomnia, alcohol dependence, ever used cannabis, SA, PTSD and OCD 
(Table 3). Totally 69 genomic risk loci were identified from the 12 pairs of comparisons (Table 3). Please refer 
to Table S1 to S12 for detailed results.  
 
MDD against SCZ 
Among the 12 pairs of comparisons, comparison of MDD and SCZ generate the largest number of 
genome-wide significant SNPs (2,312 SNPs, Table 3; sub-table 1 in Supplementary Table 1 (Table S1.1)) 
which belong to 37 genomic risk loci (Table S1.2). Although most of the candidate variants were located in 
intergenic and intronic regions (81% of variants) (Table S1.3), 65 SNPs were located in exons, including 32 
nonsynonymous variants. Heritability enrichment analyses of 53 functional annotation categories indicated 
that the heritability of SNPs was not only enriched in intronic and conserved regions [Table S1.4; 
P<1.28E-04], but also in coding regions including transcription start site (TSS) (P = 1.78E-04). Besides, 
regulatory categories such as methylation and acetylation marks were found to be enriched among significant 
variants [P < 1.57E-04].  
 
  The three gene-mapping strategies (positional, eQTL and CI mapping) generated a set of 524 unique genes, 
94 of which were implicated by all three methods (Table S1.5). Additionally, GWGAS analysis identified 953 
significant genes (Table 3; Table S1.6). Taken together, 64 genes were implicated by all four strategies. 
Among them, CACNA1C was predicted to have a very high probability of loss of function mutation 
intolerance (pLI score=1; Table S1.5). Genes differentiating MDD and SCZ were mainly enriched in the 
cortex, the anterior cingulate cortex (BA24), and the frontal cortex (BA9) regions (Table S1.8;FDR<6.0E-04). 
Cell-type enrichment analysis suggested strong associations with several kinds of neurons in the cortex and 
prefrontal cortex (Table S1.9). Moreover, this analysis also identified associations with neurons in the 
midbrain, hippocampus, and lateral geniculate nucleus(LGN) regions(Table S1.9). Conditional analyses 
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suggested neurons in the cortex, GABAergic neurons in the midbrain, and pyramidal neurons in the 
hippocampus as independent contributing neurons (after controlling for other cell types) (Table S1.10). 
 
  In gene-set enrichment analysis(GEA), the 953 GWGAS significant genes were enriched in a number of 
biological GO sets, including generation of neurons, regulation of nervous system development and central 
nervous system neuron differentiation [Table S1.11; FDR< 5.88E-03]. Other enriched pathways include 
neuronal system, alcoholism and brain-derived neurotrophic factor (BDNF) signalling pathway [Table S1.12; 
FDR< 1.86E-02]. In genetic correlation analysis, SCZ was defined as ‘case’ and MDD as (pseudo-)‘control’. 
Note that a positive genetic correlation indicates that the ‘case’ disorder is more positively associated with the 
studied trait genetically than the (pseudo-)‘control’ disorder, and vice versa. For example, we observed inverse 
genetic correlations(rg) with insomnia, neuroticism, coronary artery disease (CAD) and mean hippocampal 
volume, among others. This suggested that MDD has stronger positive genetic correlations with the above 
traits/disorders compared to SCZ. Findings of this type may shed light on different patterns of comorbidities, 
but may also be clinically informative. For instance, the significant inverse rg with CAD suggested that 
compared to SCZ patients, MDD patients may be more genetically predisposed to CAD.  
 
MDD against BPD, ED, ASD, ADHD, Anxiety disorder, Insomnia, Alcohol dependence and Cannabis use 
  In these 8 pairs of comparisons, we identified 32 differential genomic loci (Table 3; detailed in Table 
S2-S9). The comparison between MDD and BPD revealed the largest number of significant genes based on 
GWGAS (174 genes; Table 3; Table S2.6). Here we just briefly highlight the comparisons of MDD with a few 
disorders (BPD, ADHD and anxiety disorders) which yielded the largest number of significant genes in 
GWGAS.  
 
In the comparison between MDD and BPD, we found 4 significant risk loci, in which the strongest signal 
rs17751061 was found to be highly pathogenic likely influencing the function of SUGP1 (Table S2.2, CADD 
= 35). Another nonsynonymous variant, rs17420378, was located in exon 8 of STK4 (risk loci no. 4) with high 
predicted pathogenicity(Table S2.2, CADD=22.7). Besides, STK4 was implicated by all four gene-mapping 
strategies(Table S2.5 and S2.6). GEA revealed 174 GWGAS-significant genes, which were enriched in 17 
gene ontology (GO) sets[Table S2.10; P<0.01], such as transitional metal ion binding and pre-mRNA binding. 
Our pathway enrichment analysis indicated that differential genetic associations between MDD and BPD were 
involved in neural cell adhesion molecule (NCAM) signalling for neurite outgrowth, amphetamine addiction, 
serotonergic and glutamatergic synapse [Table S2.11;FDR = 4.88E-02 for all four pathways], among other 
pathways.  The differential variants were enriched in brain regions including the cerebellum, cortex, and 
frontal cortex (BA9) [Table S2.7; FDR < 4.03E-02]. Enrichment analysis within brain regions suggested that 
the cortex and frontal cortex were the most enriched compared to others[Table S2.8; FDR<5.31E-04]. The 
most significantly enriched cell type was GABAergic neurons from LGN. Interestingly, the differential 
variants (BPD vs MDD) were found to have positive correlations with childhood IQ and a higher level of 
education [Table S2.12;FDR<3.26E-02], but negative correlations with insomnia and CAD [FDR< 4.92E-03]. 
  
  In the comparison between MDD and anxiety disorders, five genetic loci were found (Table 3), one of 
which involved the extended MHC (xMHC) region (46). The top mapped genes involved a set of genes in the 
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xMHC region, and 3 other genes from other chromosomes (LRFN5, PTPN1, FAM65C) (Table 4). We note that 
due to the complex LD structure and high gene density in this region, it may be relatively difficult to identify 
the true casual gene/variant. GWGAS revealed 106 significant genes(Table S6.6). The most enriched tissues 
contributing to differential associations included the nucleus accumbens, frontal cortex and cerebellar 
hemisphere (Table S6.7); the most enriched cell types included GABAergic neurons from hippocampus, 
midbrain and temporal cortex, among others (Table S6.9).  
 
 In the comparison of MDD with ADHD, 167 significant differential genetic variants were identified which 
formed 5 genetic loci (Table S5.1 and S5.2). Four genes were mapped by all 3 gene-mapping strategies, 
including KDM4A, SLC6A9, TMEM161B and CDH8 (Table S5.5 and S5.6). Altogether 82 genes were 
significant in gene-based test, and pathway and GSEA shed light on pathways such as those related to DNA 
methylation (Table S5.10 and S5.11). The most enriched cell types included GABAergic neurons in the 
midbrain and prefrontal cortex, as well as dopaminergic neurons in the midbrain (Table S5.9).   
 
MDD against depression-related traits 
In this section, we tried to identify differential genetic variants from three pairs of comparisons between MDD 
and three depression-related phenotypes (probable recurrent severe depression, seen GP for anxiety/depression 
and longest period of feeling low/depressed). Ten risk loci were identified (Table 3, Table S13 to S15).  
 
MDD against depression defined in UKBB 
First we compared MDD (from PGC; majority clinically defined) against probable recurrent depression 
(severe)[ProbDep]. We identified 4 risk loci (Table 3;Table S13.2), including one in the xMHC region. 
Gene-based test revealed 110 significant genes. Tissue enrichment analysis highlighted the cerebellar 
hemisphere, nucleus accumbens and frontal cortex as the most enriched regions. Cell-type enrichment analysis 
suggested that the significant genes were associated with GABAergic, dopaminergic and other types of 
neurons in LGN, middle temporal gyrus (MTG), hippocampus, midbrain and cortex regions(Table S13.9). 
Pathway analysis mainly highlighted those related to DNA methylation and histone modification contributed 
by histone genes in the xMHC region; other top pathways included Rett syndrome causing genes and axon 
guidance pathway. GO sets enriched included regulation of long-term neuronal synaptic plasticity, central 
nervous system neuron development and differentiation(Table S13.11 and S13.12). Genetic correlation 
analysis showed that MDD-PGC was more positively genetically correlated with most other psychiatric 
disorders (e.g. SCZ, BPD, ASD, ADHD) as well as CAD when compared with ProbDep(Table S13.13). We 
then compared MDD against seen GP for nerves/anxiety/depression(GPDep). The significant variants mapped 
into 3 loci, 2 of which were also observed in the above analysis (including one in the xMHC region). 
Gene-based analysis revealed 72 genes; we observed an overlap of 69 genes with the previous analysis with 
ProbDep, although the latter analysis identified 110 significant genes. Other results of comparison between 
MDD and GPDep are shown in detail in Tables S14.  
 
MDD against duration of longest period of feeling low/depressed (top quintile as case)  
For this comparison, functional annotation of 133 candidate SNPs formed 3 genetic risk loci, among which 
the GRIK2 gene was also mapped by the three gene-mapping methods (positional, eQTL, CI mapping; Table 
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S15.5). The gene codes the Glutamate Ionotropic Receptor Kainate Type Subunit 2, suggesting glutamatergic 
transmission may be one factor with differential associations between susceptibility to depression and severity 
(as reflected by duration) of illness. Possibly due to limited sample size, tissue and cell-type enrichment 
analysis did not reveal significant results.  
 
Neuroticism against SCZ/MDD/Anxiety disorder/alcohol dependence  
  In this part, five sets of GWAS summary statistics were employed which formed four pairs of comparisons 
(neuroticism against anxiety disorder, SCZ, MDD and alcohol dependence; Table 2). The choice is based on 
relatively high association of neuroticism with these disorders (47-49). We identified 1,294 genomic risk loci 
from the four comparisons (Table 3). For space limits, we highlight the results of neuroticism vs MDD only 
(Table S16). Please refer to Tables S17-S19 for detailed findings of other comparisons.  
   
In the comparison of neuroticism against MDD, 20 risk loci were identified(Table S16.1 and S16.2). 
Functional annotations of 5,573 candidate SNPs in these loci highlighted a number of genes, among which 
CRHR1, MAPT, WNT3 and KANSL1 were mapped by all 3 gene-mapping methods and MAGMA (Table S16.5 
and S16.6). They all belong to a risk locus on chr 17 but the exact causal gene(s) may require clarification in 
further studies. Tissue enrichment analysis observed enriched signals in most brain regions(Table S16.7); 
within-brain comparison showed that the cortex, frontal cortex, anterior cingulate cortex and nucleus 
accumbens were the most enriched [Table S16.8; FDR<1.40E-02]. Cell-type enrichment analysis of the 
GWGAS-significant genes suggested that they were mainly enriched in the LGN region (P (FDR within one 
dataset)<4.40E-02; Table S18.9). GO set enrichment analysis revealed that axon extension, CNS neuron 
differentiation and regulation of neuron death may be involved (Table S16.10).  
 
Psychotic experiences against SCZ/BPD/MDD 
Here we identified 10 and 2 genomic risk loci from comparison of psychotic experiences against SCZ and 
BPD respectively, but not from psychotic experiences against MDD (Table 3; Table S20-S22).   
 
Psychotic experiences against SCZ 
  In this comparison, functional annotation of 1,749 candidate SNPs revealed 10 genomic risk loci, covering 
82 genes (Table S20.2). Altogether 68 genes were mapped by all three gene-mapping strategies, over half of 
which (35/68) was also indicated by GWGAS analysis (Table S20.5 and S20.6). The most implicated brain 
regions were the cortex, frontal cortex(BA9) and anterior cingulate cortex (Table S20.8). Cell-type enrichment 
analysis also observed significant signals in cortex and prefrontal cortex as the top two findings (Table S20.9). 
Enriched pathways or gene-sets included anterograde trans-synaptic signalling, synaptic vesicle exocytosis/ 
localization and synaptic adhesion-like molecules (Table S20.11 and S20.12).  
 
Psychotic experiences and BPD 
Functional annotation analysis highlighted several genes (SUGP1, GATAD2A and CILP2) harbouring SNPs 
with very high CADD scores (CADD score> 13.31, Table S21.2). The 3 gene-mapping strategies mapped 
variants to 10 genes(Table S21.5), all of which were also identified by GWGAS(Table S21.6). Tissue 
enrichment analysis suggested enrichment in the cortex, cerebellar hemisphere, frontal cortex, anterior 
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cingulate cortex and cerebellum regions (FDR<2.99E-02; Table S21.7 and S21.8). Further analysis 
highlighted cocaine and amphetamine addiction, PTEN and EGF signalling as top pathways (Table S21.11).  
 
Psychotic experiences and MDD 
Although the comparison did not generate any significant differential variants, a few genes were 
highlighted via functional annotations of candidate SNPs (Table S22.2). All of the three gene-mapping 
strategies linked variants to 9 protein-coding genes (TMEFF2, SLC30A9, BEND4, PRLR, EPM2A, FBXO30, 
SHPRH, GRM1, ANK3; Table S22.5). Genetic correlation analysis suggested that MDD showed stronger rg 
with SCZ or BPD compared to psychotic experiences (Table S22.10).  
   
Other pairs of comparisons 
We also applied the proposed methods to the other four clinically relevant comparisons, including SCZ against 
BPD, ADHD against ASD, alcohol dependence against ever used cannabis and anxiety disorder against SA 
(Table 3). We identified 3, 7, 2 and 1 genomic risk loci from each of the comparison respectively (Table 3). 
Here we highlight the results from SCZ vs BPD and ADHD vs. ASD as examples (please refer to Tables 
S23-S26 for details). 
 
SCZ vs BPD 
Our analytic results based on GWAS summary data showed almost perfect genetic correlation with those 
obtained by comparing BPD and SCZ using individual genotype data (10) (rg =1.054, se=0.025). 
 
   As for the actual results, we observed three significant loci in the comparison of SCZ and BPD (Table 3).  
GWGAS highlighted 144 significant genes which were enriched for brain regions [Table S23.7; 
FDR<1.87E-02]. The frontal cortex and anterior cingulate cortex were the most enriched regions compared to 
other brain regions [Table S23.8; FDR< 2.55E-02]. Furthermore, cell-type enrichment analysis identified an 
enrichment signal in three different types of neurons in the midbrain region [Table S23.9; P<4.01E-03], which 
could withstand multiple testing correction within the corresponding dataset(FDR=3.34E-02). The enriched 
pathways included the inositol metabolism pathway and those related to cellular senescence [Table S23.11; 
FDR = 2.51E-02]. 
 
ADHD vs ASD 
  In the comparison between ADHD and ASD, 7 risk loci were found (Table S24.2). Seven genes (KDM4A, 
ERI1, SOX7, PINX1, XKR6, MTMR9 and SEMA6D; Table S24.5 and S24.6) were highlighted by all three 
gene-mapping methods and GWGAS (Table S24.5 and S24.6). We observed that ADHD may have stronger 
positive rg with CAD and insomnia compared to ASD; however, the reverse was observed for years of 
education, parental age at death and intra-cranial volume (Table S24.12).   
 
Ability to distinguish between disorders based on PRS  
Ability to distinguish between disorders based on PRS derived from current GWAS data  
The results are presented in Table 5. In the analysis, we assume each subject is either having one of the 
disorders. Taking SCZ vs MDD as an example, we assume the differential diagnosis(ddx) has been narrowed 
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down to either SCZ or MDD. The prior probabilities (without genetic information) of being affected with 
either disorder are based on lifetime prevalence of the two disorders (14, 50). For example, here we assume 
that a person has ~13/0.5=26 times of being affected by MDD than SCZ (i.e. RR~26), in the absence of 
additional information. Our analytic framework actually allows more flexible setting of these prior 
probabilities, although we made simpler assumptions here. We expect that with the addition of polygenic 
scores, one would be able to differentiate the disorders more accurately. A good prediction model leads to 
more spread-out predicted risks and larger relative risks when we compare subjects at the top and bottom 
percentiles.    
  Subjects at the lowest 5th percentile of the PRS distribution (SCZ as ‘case’ and MDD as ‘control’) have a 
markedly lower risk of SCZ than MDD compared to the population average. In this case, RR of MDD vs SCZ 
was 125.3 for a person with PRS at the bottom 5th percentile (average RR=26) (Table S1.15). With an increase 
in PRS, the risk of SCZ became higher, while the risk of MDD reduced. Subjects at the highest 5% of the risk 
score (of SCZ vs MDD) had a substantially decreased RR of 10.16. Note that at the start we assume ~26 times 
higher risks of MDD than SCZ based on overall lifetime risks; a reduction of this ratio to 10.16 times is a 
relatively large change. We also present the RR of the ‘case’ disorder by comparing individuals at the highest 
and lowest xth percentiles. For example, the estimated RR of SCZ was 11.31 if we compare those at the 
highest 5th against those at the lowest 5th percentile. For SCZ vs BPD and BPD vs MDD, the corresponding 
RR (for the 1st disorder) was 3.29 and 2.82 respectively.  
  For most other comparisons, the AUC based on PRS of existing GWAS data were modest, and so were the 
corresponding RR comparing those at high and low percentiles. However, two other pairs of traits/disorders 
(SCZ vs psychotic experience and ADHD vs ASD) were estimated to attain an AUC>0.6.  
 
Maximum achievable AUC based on SNP-based heritability 
The maximum AUC that can be attained (at SNP-based heritability) is presented in Table 5. The levels were 
much higher than the current AUC, indicating room for improving discriminating ability by increasing sample 
sizes. Besides, we also computed other predictive indices and graphs which are shown in the supplementary 
tables.  
 
Discussion 
The present study applied a simple yet useful analytic framework to identify differential genetic markers for a 
board range of psychiatric disorders/traits. We conducted detailed secondary analysis to identify the genes, 
pathways and cell-types/tissues implicated. From the 26 pairs of comparisons, we identified a total of 11,410 
significantly associated differential variants, 1,398 genomic risk loci and 3,362 significant genes from 
GWGAS with FDR<0.05.  
 
SNP-based heritability (h2snp) of differential genetic associations 
Interestingly, we found that the SNP-based heritabilities were significantly different from zero for almost all 
comparisons, with some having moderately high heritabilities. This suggests that genetic differences (due to 
common variants) may at least partially underlie the differences between psychiatric disorders, even for 
closely related ones such as MDD and anxiety disorders, or SCZ and BPD.  
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  For MDD and comparisons with other disorders, we observed the highest h2snp in the comparison with SCZ, 
BPD, ED and anxiety disorders. For instance, despite substantial symptom overlap (51) between MDD and 
anxiety disorders, the h2snp is among the highest at ~36% (by SumHer; liability scale). On the other hand, h2snp 
was estimated at ~1% only when comparing MDD to PTSD. A possible explanation is that environmental 
factors (e.g. traumatic stressors must be present for PTSD but not MDD) may play an important role in 
explaining the differences between the latter two disorders. For neuroticism against other psychiatric disorders, 
the h2snp were in general low; however, h2snp for neuroticism itself was only ~10%, based on one of the largest 
meta-analysis to date (52).  
 
We wish to highlight a difference between genetic correlation (rg) (between two traits) and the h2snp from 
the differential association test. Note that two variables can have a high correlation if there is a strong linear 
relationship, but the actual values of the variables can differ. It is possible that two traits have a relatively high 
genetic correlation (rg), but as the effect sizes of SNPs can differ, h2snp can still be substantial. Nevertheless, 
there are several caveats when interpreting h2snp. First, large sample sizes are often required for SNP-based 
heritability analysis. However, for several disorders the samples sizes were relatively moderate (e.g. OCD and 
ED), as a result the estimates could be imprecise. Also, contribution of rare variants and other ‘omic’ changes 
such as epigenetic changes were not captured by h2snp. Moreover, estimation of h2snp is subject to model 
assumptions(41) of genetic architecture, which can vary among diseases. 
 
Ability to distinguish between psychiatric disorders based on polygenic risk scores (PRS) from common 
variants 
A potential translational aspect is to make use of PRS from SNPs to distinguish between psychiatric disorders. 
This is particularly relevant in psychiatry due to the lack of objective biomarkers. In a recent study, Liebers et 
al. studied if PRS may discriminate BPD from MDD. They found that subjects at the top decile of BPD PRS 
were significantly more likely to have BPD than MDD, when compared to those in the lowest decile. The 
estimated odds ratio was 3.39 (95% CI 2.19–5.25), which is comparable to our relative risk estimate (2.24) 
based on our analytic approach using GWAS summary statistics (see Table 5) (relative risk are usually smaller 
than ORs). Among the comparisons, differential diagnosis between MDD and BPD is perhaps one of the most 
clinically relevant, as it is sometimes difficult to distinguish the two from clinical symptoms alone and the 
treatment is different. Based on present GWAS data, the AUC for discriminating BPD vs MDD is 0.602 (at the 
best p-value threshold), which is modest. However, PRS may be more informative for individuals at the 
extreme end of the score. The discriminating power between BPD and SCZ was similarly modest (best 
AUC=0.618) but the AUC for SCZ vs MDD was much higher (0.694). Clinically, major depression (mainly 
psychotic depression) may be a DDx for first-episode psychosis(53); it may be interesting to study if PRS can 
help distinguish SCZ from MDD in such patients. We also estimated the maximum discriminatory ability by 
PRS based on h2snp (i.e. assuming all common variants are found); the maximum estimated AUC for MDD vs 
BPD, SCZ vs BPD and SCZ vs MDD were 0.749, 0.726 and 0.763 respectively. These findings suggest that 
with larger GWAS sample sizes, PRS may become more informative and may help DDx of related disorders.  
 
   Another interesting analysis is on how well PRS can differentiate ‘psychotic experience’(PE) against 
psychiatric disorders such as SCZ, BPD and MDD, which may all present with psychotic symptoms. 
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Interestingly, the h2snp of PE vs SCZ or BPD were both high (0.356 and 0.398 respectively) and the maximum 
AUC based on this SNP-based heritability were over 0.8. However, based on present GWAS data, the 
corresponding discriminatory power was weaker (all AUC<0.7), suggesting there is potential for PRS to help 
distinguish PE from psychiatric disorders but larger studies were required. Nevertheless, individuals with 
more extreme PRS show more substantial differences in disease risks; for example, in the comparison 
between SCZ vs PE, the risk of SCZ for subjects at the 95th percentile of PRS was 9.19 times of those at the 
5th percentile. The corresponding RR was 5.62 when comparing the 90th and 10th percentiles.  
 
Several limitations are worth noting. For some pairs of comparisons (e.g. MDD vs other disorders), 
comorbidities are possible; whether it is clinically helpful to use PRS to guide DDx will depend on the clinical 
context. In practice, we expect clinical symptoms and features still remain very important in making DDx. 
Genomic data, for example in the form of PRS, may provide additional discriminatory power when integrated 
with clinical features. Also, since we relied on summary statistics, we applied an analytic approach (11) to 
estimate the AUC from current GWAS samples. Limitations of this methodology was detailed in (11). Mainly, 
we assume the predictive model will be applied to the same population as the training data. Nevertheless, as 
patients with the same psychiatric disorder can be heterogeneous, and PRS may need to be applied across 
different ethnic groups, the estimated AUCS may be optimistic in this regard. Ideally, predictive power should 
also be further evaluated in an independent set with individual genotype data. In addition, our analytic 
approach for forecasting AUC assumed a (standard) p-value thresholding and LD-clumping (P+T) approach to 
be employed. While this approach is widely adopted, newer PRS modelling methodologies (e.g. LDpred; see 
(54) for a review) may be used to further improve predictive power.  
 
Comparison of MDD-PGC with depression-related traits in UKBB  
We performed another interesting comparison between MDD-PGC and other depression-related traits from 
UKBB. The former group was mainly composed of clinically diagnosed MDD, while the latter group was 
largely defined by self-reporting. For example, for recurrent severe probable depression (ProbDep), it included 
subjects who reported ever feeling depressed or disinterested for one week, with >=2 episodes lasting for >=2 
weeks, and have visited a psychiatrist for mood problems. The other phenotype studied was having seen GP 
for depression/nerves/anxiety. Neither of the two traits involved assessment of clinical symptoms as described 
in DSM/ICD. Based on our analysis, the (non-overlapping genetic component of) MDD-PGC appeared to be 
more strongly genetically correlated with other psychiatric disorders (e.g. SCZ, BPD, anorexia, ASD, ADHD) 
and other outcomes such as CAD, when compared with non-clinically-defined depression in UKBB. It is 
worth noting that while rg between MDD-PGC and UKBB depression traits were very high, the SNP-based 
heritability from the differential genetic analysis was significantly higher than zero. One possible explanation 
is that while many susceptibility genes may be shared between the traits, the effect sizes may differ. Another 
point to note is that rg based on LDSC may be over-estimated in case-control studies due to difficulties in 
handling covariates(55). The latter was also reported in (56) when comparing LDSC against a more 
sophisticated method PCGC (55).  
 
  A recent work by Cai et al.(56) suggested that depression traits defined by ‘minimal phenotyping’ (ProbDep 
and GPDep included here also belonged to ‘minimal phenotyping’ by Cai et al.) are genetically different from 
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strictly defined MDD. For example, they have lower h2snp and have worse predictive power in MDD cohorts. 
Cai et al. focused on comparisons of different definitions of ‘depression’ within UKBB, while here we mainly 
compared the genetic architecture of MDD-PGC against traits in UKBB; we also employed a different 
statistical approach. Our results supported differences in genetic basis between different definitions of 
depression, and calls for more in-depth phenotyping to study depression and related traits.  
 
Tissue/cell-type enrichment analysis 
In view of the large number of comparisons performed, we just highlighted a few results for discussion. The 
tissue/cell-type enrichment analysis implied that the frontal cortex (BA9) and anterior cingulate cortex (ACC; 
BA24) may be implicated in the difference between several disorders, such as MDD against SCZ/BPD, 
neuroticism against MDD/alcohol dependence, and psychotic experiences against SCZ/BPD. BA9 contributes 
to the dorsolateral and medial prefrontal cortex, dysfunction of which underlies many cognitive and 
behavioural disturbances that are associated with psychiatric disorders, such as SCZ, MDD, ADHD, and ASD 
(57, 58). The ACC is involved in many functional roles of the brain, including affective, cognitive and motor 
aspects (59). A number of studies have suggested that functioning alterations in the ACC may be implicated in 
psychiatric disorders such as MDD(60), BPD(61) and SCZ(62). It is possible that different patterns of 
dysfunctioning in these brain regions may underlie the differences between disorders. Cell-type enrichment 
analysis may also help to pinpoint the cell-types (and brain regions) involved in differentiating the disorders. 
For example, when comparing MDD vs anxiety disorders, the most enriched cell types were GABAergic 
neurons from hippocampus, midbrain and temporal cortex. Interestingly, benzodiazepines, one of the most 
widely prescribed drugs for anxiety, acts on the GABAergic pathway, while antidepressants primarily target 
the monoamine system. With increasing amount of single-cell RNA-seq data in the future, cell-type 
enrichment analysis may delineate more precisely the specific type of neurons.  
 
Genetic correlation analysis 
We just briefly highlight a few examples of our findings. For example, in the comparison of BPD vs MDD, 
we observed positive genetic correlation (rg) with childhood intelligence and level of education (Table S2), 
suggesting that BPD is more strongly genetically linked to these traits. Concordant with this finding, it was 
reported that low IQ was associated with severe depression and SCZ but not BPD (63). Slightly unexpectedly, 
we also observed positive rg with anorexia nervosa (AN), although AN is more commonly comorbid with 
depression clinically. Similarly, when comparing SCZ vs MDD, positive rg was also observed. One hypothesis 
is that the high comorbidity of AN with MDD may be partially attributable to environmental factors (64).  
Genetic correlation analysis may also shed light on the brain regions implicated in different disorders. For 
the comparison of SCZ vs MDD, we observed a significant negative correlation with hippocampal volume, 
which was corroborated by associations in the hippocampus region in cell-type enrichment analysis. Both 
SCZ and MDD patients have been reported to have smaller hippocampal volumes compared to healthy 
controls (65, 66). However, a comparative study showed that there was a larger reduction in hippocampal 
volumes in SCZ patients compared to those with MDD (67). Our genetic correlation analysis seemed to 
support this finding.  
  
Many limitations of this study have been detailed above. As for other limitations, we note that the 
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methodology assumes the controls of both GWAS datasets originate from a similar population. If the 
heterogeneity is high (e.g. from different ethnic groups), the estimates may be biased. As a related limitation, 
most of the studies were based on European samples; the effects of the genetic loci identified may differ 
across populations, and PRS derived from European samples may have poorer predictive abilities in other 
ethnicities.  
 
Conclusions 
In summary, our analytic framework successfully identified a number of differential genomic risk loci 
from 26 pairs of comparisons of psychiatric traits/disorders. Moreover, further analysis revealed many novel 
genes, pathways, brain regions and specific cell types implicated in the differences between disorders. We also 
showed that PRS may aid differentiation of some psychiatric disorders(e.g. MDD vs BPD) to a certain extent, 
but further clinical studies are required to confirm the findings. With the increasing size of GWAS samples, 
genetic information may provide useful information for more accurate diagnosis and personalized treatment of 
psychiatric disorders.  
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Figure 1 legends 
Summary of our analysis framework. GWAS summary statistics of the two traits under study were 
harmonized and differential genetic associations were identified by the method we described in main text. The 
power of polygenic scores (derived from the above association test treating the first disorder as ‘case’ and the 
second one as ‘control’) to differentiate the two disorders was computed. We computed two sets of 
discriminatory power estimates, one based on existing GWAS data, the other based on SNP-based heritability, 
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reflecting the maximum achievable discriminatory power. We also investigated the genetic correlation (mainly 
using LD score regression [LDSC]) with other possible comorbid traits/disorders. We also performed 
genome-wide gene-based association study (GWGAS) to identify associated genes, and the most relevant 
tissues, cell-types and pathways implicated. As a parallel analysis, we performed functional annotations and 
mapped the SNPs to relevant genes based on gene positions, expression quantitative trait loci (eQTL) and 
chromatin interaction (CI) data. 
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Tables 
Table 1 Simulation results comparing analyses of individual-level genotype data and our presented analytic approach 
Overlap rate No. cases h2A h2B 
Correlation RMSE Inferred Real GWAS 
Beta SE Beta SE Power 
Type I  
Power 
Type I  
error error 
0.15 
10000 0.2 0.3 0.98769 0.99789 0.02194 0.00803 0.633 0.040 0.723 0.043 
20000 0.2 0.3 0.99335 0.99807 0.01634 0.00564 0.740 0.040 0.770 0.037 
50000 0.2 0.3 0.99766 0.99811 0.00939 0.00359 0.823 0.023 0.873 0.047 
100000 0.2 0.3 0.99861 0.99811 0.00724 0.00253 0.877 0.047 0.903 0.047 
10000 0.22 0.32 0.98766 0.99776 0.02253 0.00800 0.653 ------ 0.723 ------ 
20000 0.22 0.32 0.99376 0.99794 0.01618 0.00565 0.723 ------ 0.787 ------ 
50000 0.22 0.32 0.99784 0.99792 0.00941 0.00360 0.833 ------ 0.880 ------ 
100000 0.22 0.32 0.99873 0.99796 0.00724 0.00254 0.877 ------ 0.910 ------ 
0.25 
10000 0.2 0.3 0.99022 0.99768 0.02077 0.00606 0.660 0.040 0.717 0.043 
20000 0.2 0.3 0.99645 0.99764 0.01243 0.00437 0.737 0.037 0.770 0.030 
50000 0.2 0.3 0.99816 0.99785 0.00898 0.00275 0.817 0.043 0.857 0.050 
100000 0.2 0.3 0.99913 0.99777 0.00608 0.00194 0.870 0.040 0.900 0.027 
10000 0.22 0.32 0.99144 0.99730 0.02031 0.00605 0.683 ------ 0.727 ------ 
20000 0.22 0.32 0.99637 0.99754 0.01315 0.00436 0.757 ------ 0.780 ------ 
50000 0.22 0.32 0.99831 0.99771 0.00888 0.00275 0.833 ------ 0.860 ------ 
100000 0.22 0.32 0.99923 0.99760 0.00597 0.00194 0.887 ------ 0.903 ------ 
No. cases indicates the number of cases we defined for our simulation scenarios; h2 , heritability explained by SNPs; RMSE, root mean square error. 
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Table 2. Summary of GWAS data of 18 psychiatric traits/disorders included in this study 
Traits/Disorders Abbreviation Source b Data type Cases Controls Total N Prevalence (%) d 
Major Depression Disorder (2018)  MDD PGC binary 59,851 113,154 173,005 13.0 (12) 
Bipolar Disorder (2018) BPD PGC binary 20,129 21,524 41,653 2.4 (13) 
Schizophrenia (2018) SCZ GERAD&CRESTAR binary 40,675 64,643 105,318 0.5 (14) 
Autism Spectrum Disorder (2019) ASD iPSYCH&PGC binary 18,381 27,969 46,350 2.5 (15) 
Attention deficit hyperactivity disorder (2019) ADHD iPSYCH&PGC binary 19,099 34,194 53,293 6.5 (16) 
Post-traumatic Stress Disorder (2017) PTSD PGC binary 5,183 15,547 20,730 3.9 (68) 
Anxiety Disorder (2018) a anxiety UKBB binary 16,730 101,021 117,751 14.2 e 
Eating Disorder (2017) ED PGC binary 3,495 10,892 14,477 1.2 (17) 
Obsessive-compulsive Disorder (2018) OCD PGC binary 2,688 7,037 9,725 2.3 (18) 
Insomnia (2019) Insomnia UKBB&CTG lab binary 109,389 277,144 386,533 10.0 (19) 
Suicide Attempts in mental disorder (2018) SA iPSYCH-PGC binary 6,024 44,240 50,264 2.7 (20) 
Alcohol dependence (2018) alcohol PGC binary 11,476 23,080 34,556 12.0 (21) 
Ever used cannabis (2018) cannabis ICC binary 43,380 118,702 162,082 4.0 (22) 
Psychotic Experiences (2019) PE CNGG-Walters group binary 6,123 121,843 127,966 5.8 (23) 
Neuroticism_High_20P (2019) neuroticism CTG Lab binary c 78,056 312,222 390,278 20.0 c 
Longest period of depression_High_20P (2018)  longest depression UKBB binary c 10,133 40,531 50,664 20.0 c 
Bipolar and major depression status:  
Probable Recurrent major depression 
ProbDep UKBB binary 6,304 80,591 86,895 3.55 (24) 
Seen doctor (GP) for nerves, anxiety, tension 
or depression 
GPDep UKBB binary 123,528 235,165 358,693 17.3 (12) 
a Anxiety Disorder: mental health problems ever diagnosed by a professional: anxiety, nerves, or generalized anxiety disorder; b PGC: psychiatric genomics consortium; UKBB: UK biobank; CTG lab: complex trait 
genetics lab; ICC: international cannabis consortium; CNGG: Centre for Neuropsychiatric Genetics and Genomics; c continuous neuroticism scores were transformed to binary traits, in which 20% of subjects were 
assigned as cases and the others as controls; population prevalence of longest depression is population prevalence of MDD multiple by 20%, i.e. 13%*20%. d Prevalence of traits/disorders refers to estimates of 
lifetime prevalence based on the cited references; e Prevalence of anxiety disorder is estimated from UKBB directly. 
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Table 3. Identification of differentially associated genetic variants/genes from correlated psychiatric traits/disorders. 
Comparisons a 
Genetic correlation Differential association GWASb 
rg p-value intercept Sig. SNPs Genomic risk loci Sig. Genes LDSC-h2 (se) SumHer-h2 (se) 
1.MDD vs. psychiatric disorders/traits         
 
SCZ 0.3857 3.50e-46 0.0548 2,312 37 953 0.183(0.008) 0.220 (0.085) 
BPD 0.3387 1.82e-23 0.0679 42 4 174 0.239(0.013)  0.297 (0.040) 
ED 0.1652 1.29e-02 0.0433 94 2 5 0.258(0.035)  0.319 (0.067) 
ASD 0.4466 6.97e-25 0.1441 76 5 17 0.147(0.015) - d 
ADHD 0.5573 1.33e-50 0.1703 167 5 82 0.198(0.018)  0.162 (0.090) 
anxiety 0.7851 1.87e-32 0.0341 120 5 106 0.284(0.019) 0.363 (0.035) 
insomnia 0.4706 1.75e-44 0.004 13 3 40 0.083(0.006)  0.099 (0.011) 
alcohol 0.5893 4.23e-09 0.0389 3 1 0 0.064(0.016) 0.088 (0.058) 
cannabis 0.2433 8.61e-09 -0.0009 608 7 24 0.122(0.009) 0.133 (0.016) 
SA 0.5639 8.00e-04 0.0069 0 14 c 0 0.056(0.023)  0.117 (0.048) 
PTSD 0.6095 7.70e-03 0.0064 0 9 c 0 0.034(0.024) 0.010 (0.048) 
OCD 0.2272 5.00e-04 0.0103 0 12 c 1 0.344(0.050)  0.262 (0.081) 
2.MDD vs. depression-related traits (from 
UKBB) 
   
    
 
 Recurrent probable depression 1.1036 7.99e-12 0.0617 177 4 110 0.505(0.033) 0.613 (0.055) 
 seen GP for depression 0.9441 6.84e-287 0.0978 22 3 72 0.087(0.007)  0.111 (0.012) 
 longest depression 1.0821 1.21e-06 0.0286 3 3 0 0.020(0.003)  0.021 (0.006) 
3. Neuroticism vs. psychiatric disorders         
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    anxiety 0.7401 7.24e-49 0.1617 4,671 57 1,232 0.161(0.006)  0.259 (0.076) 
    SCZ 0.2293 1.10e-20 0.0102 1,733 1,214 1 0.013(0.001)  0.009 (0.003) 
    MDD 0.7507 6.54e-182 0.0644 65 20 4 0.016(0.001)  0.021 (0.001) 
    alcohol 0.3754 7.66e-08 0.008 37 3 40 0.022(0.004)  0.105 (0.004) 
 
4.Psychotic experiences vs. common disorders 
   
   
  
 SCZ 0.2014 1.00e-04 0.009 731 10 239 0.356(0.022)  0.330 (0.043) 
 BPD 0.1748 2.36e-02 0.0056 25 2 30 0.398(0.033)  0.587 (0.083) 
 MDD 0.4957 1.33e-08 0.0072 0 11 c 0 0.131(0.022)  - d 
5. Four other comparisons         
SCZ vs. BPD 0.6903 2.13e-181 0.1403 45 3 144 0.202(0.015)  0.378 (0.071) 
ASD vs. ADHD 0.3879 4.89e-17 0.3444 335 7 88 0.400(0.033) 0.438 (0.063) 
alcohol vs. cannabis 0.1482 5.20e-02 0.022 130 2 0 0.132(0.019)  0.187 (0.027) 
anxiety vs. SA 0.0705 7.31e-01 0.0068 1 1 0 0.072(0.036)  0.137 (0.065) 
a MDD: major depression disorder, SCZ: schizophrenia, BPD: bipolar disorder, ED: eating disorder (anorexia nervosa), PTSD: posttraumatic stress disorder, OCD: obsessive-compulsive disorder, ASD: autism 
spectrum disorder, ADHD: attention deficit hyperactivity disorder; Used cannabis: ever used cannabis; Longest depression: Longest period of depression; Seen GP for depression: Seen general practitioner (GP) for 
nerves, anxiety, tension or depression; Severe depression: Bipolar and major depression status: Probable Recurrent major depression; SA: suicide attempts.  
b Sig. SNPs: SNPs with nominal p values below 5e-08; Sig. Genes: Genes with adjusted p-value (FDR) below 0.05 in GWGAS; LDSC/SumHer-h2: liability-scale SNP-based heritability calculating by the LDSC and 
SumHer programs, respectively. 
c The corresponding genomic risk loci are constructed on those lead SNPs with p-value below 5e-06. Values of AUC above 0.70 are in bold.      
d SumHer returns estimates that are negative, hence we present the results from LDSC only.
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Table 4. Top 5 genes from each comparison based on gene-based analysis using MAGMA. 
Comparison Top 5 genes P FDR-adjusted P 
SCZ vs MDD PPP1R16B,HIST1H4L, DPYD, PITPNM2, NGEF <5.44E-12 <1.99E-08 
BPD vs MDD HAPLN4, TRANK1, VPS9D1, MAD1L1, NDUFA13 <4.24E-07 <1.33E-03 
MDD vs ASD MACROD2, XRN2, WDPCP, EGR2, FZD5 <4.00E-06 <1.27E-02 
MDD vs ADHD CDH8, MEF2C, KDM4A, PTPRF, KCNH3 <2.02E-07 <7.48E-04 
MDD vs ED ERBB3, SUOX, FAM19A2, CRTC3, RAB5B <5.58E-06 <2.09E-02 
MDD vs anxiety BTN3A2, HIST1H2BN, PTPN1, ZKSCAN4, PGBD1 <3.54E-08 <1.33E-04 
MDD vs. insomnia 
BTN3A2, HIST1H2BN, ZSCAN9, SYNGAP1, 
RAB1B 
<4.98E-07 <3.81E-03 
MDD vs. alcohol MTFR1, ATF6B, KREMEN2, SLC25A52, ALPK1 <1.35E-04 <4.47E-01 
MDD vs. cannabis CADM2, C10orf32-ASMT, AS3MT, ACTL8, ARID1B <3.80E-07 <1.43E-03 
MDD vs. SA NCL, ST8SIA5, COA4, PDE4B, SLBP <1.46E-04 <3.99E-01 
MDD vs PTSD ATP6V1E1, MYO5B, ZYG11A, GNA15, UBA3 <3.04E-04 <8.89E-01 
MDD vs OCD KIT, PLAG1, FGF19, PPIG, TXNL1 <3.31E-05 <8.88E-02 
MDD vs. 
severe depression 
HIST1H2BN, BTN3A2, ZKSCAN4, PGBD1, PTPN1 <3.89E-08 <1.47E-04 
MDD vs. seen GP for 
depression 
PTPN1, BTN3A2, ZKSCAN4, HIST1H2BN, PGBD1 <1.54E-07 <5.81E-04 
Longest depression vs. MDD 
FBXW4, C11orf42, AC079602.1, ANAPC11, 
HIST1H2BM 
<1.56E-03 <8.33E-01 
Neuroticism vs. anxiety STH, WNT3, SPPL2C, CRHR1, MAPT <4.16E-22 <1.57E-18 
Neuroticism vs. SCZ DNAJC19,CCL20, OR7D4, PBX2, REG3A <5.65E-05 <2.01E-01 
Neuroticism vs. MDD MAPT, WNT3, CRHR1, KANSL1, NSF <1.73E-05 <6.50E-02 
Neuroticism vs. alcohol 
BTN3A2, HIST1H2BN, ZSCAN9, SYNGAP1, 
RAB1B 
<4.98E-07 <3.81E-03 
Psychotic experiences vs. 
SCZ 
SPATS2L, HIST1H4L, UBD, OR2B2, HIST1H2BN <6.47E-10 <2.02E-06 
Psychotic experiences vs. 
BPD 
SPATS2L, HAPLN4, TM6SF2, NDUFA13, 
CTC-260F20.3 
<3.73E-07 <1.24E-03 
Psychotic experiences vs. 
MDD 
FAM168A, SHPRH, SPAM1, ADRB2, POC1B <1.48E-04 <3.66E-01 
SCZ vs BPD ZKSCAN3, ZSCAN31, PGBD1, HYDIN, ZSCAN12 <6.52E-08 <2.38E-04 
ADHD vs ASD XKR6, KDM4A, C8orf12, RP1L1, MSRA <1.52E-08 <5.65E-05 
Cannabis vs alcohol HS6ST1, ABHD14A-ACY1, ACY1, ENTPD4, AKR1C2 <6.81E-05 <2.10E-01 
Anxiety vs SA PDE4B, DNAJC6, LAMA2, NCL, RAVER1 <3.96E-05 <1.45E-01 
Genes with FDR<0.05 are in bold. 
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Table 5.Ability to discriminate psychiatric disorders by polygenic risk scores (PRS) 
Comparison 
Discriminating Ability  
Relative risk of the 1st disorder comparing the top against 
the bottom percentiles (based on existing GWAS) 
AUC 
Polygenic risk scores (based 
on existing GWAS)  
Top 5th vs. 
lowest 5th  
Top 10th vs. 
lowest 10th  
Top 20th vs. 
lowest 20th  
Top 30th vs. 
lowest 30th  
(Max) Best P-thres AUC  percentile percentile percentile percentile 
SCZ vs. MDD 0.763 0.005 0.694 
 
11.31  6.61  3.46  2.17  
BPD vs. MDD 0.749 0.005 0.602 
 
2.82  2.24  1.70  1.39  
MDD vs. ED 0.78 0.0005 0.587 
 
1.09  1.07  1.04  1.03  
MDD vs. ASD 0.694 0.01 0.551 
 
1.10  1.08  1.05  1.03  
MDD vs. ADHD 0.707 0.005 0.583 
 
1.38  1.29  1.18  1.11  
MDD vs. anxiety 0.744 0.001 0.57 
 
1.54  1.40  1.25  1.15  
MDD vs. OCD 0.8 0.005 0.566 
 
1.12  1.09  1.06  1.04  
SCZ vs Psychotic 
experiences 
0.828 0.005 0.686  9.19  5.62  3.11  2.03  
BPD vs Psychotic 
experiences 
0.801 0.005 0.584  2.02  1.73  1.43  1.25  
MDD vs Psychotic 
experiences 
0.668 0.00001 0.524  1.09  1.07  1.04  1.03  
SCZ vs. BPD 0.726 0.005 0.618 
 
3.29  2.53  1.84  1.46  
ADHD vs. ASD 0.804 0.001 0.622  1.50  1.37  1.23  1.14  
AUC: area under the ROC curve; Maximum: the maximum discriminating ability (in AUC) for the 2 traits in each 
comparison based on SNP-based heritability, assuming that all risk variants in the GWAS panel were found; Values of 
AUC above 0.7 were in bold. Best P-thres: the p-value threshold for PRS analysis leading to the highest AUC. The last 
four columns show the relative risk of the 1st disorder at the top xth against the lowest xth percentiles of PRS (derived 
from treating disorder A as ‘case’ and disorder B as ‘control’) 
MDD vs PTSD was not listed above as the results from GWAS analysis were too weak in power so the AUC based on 
PRS of current GWAS data cannot be estimated. The maximum AUC (based on SNP-based h2) was estimated to be 0.588. 
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